ArticleHemaSphere2026
Validation of the new IMS/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients.
Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to its high clinical and biological complexity, multiple myeloma (MM) is a malignancy of heterogeneous prognoses and outcomes. The International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) formulated a consensus genomic staging (CGS) of high-risk MM (HRMM), aiming to refine and homogenize the classification of high-risk disease. We evaluated the new HRMM criteria in a cohort of 1209 consecutive newly diagnosed MM patients with complete CGS data (except TP53 mutations), treated in a single center with contemporary regimens, including triplets and quadruplets, between 2010 and 2024. Based on CGS criteria, 25.2% of our cohort's patients were classified as HRMM. High-risk status was associated with significantly inferior outcomes: median overall survival (OS) was 44 months for HRMM versus 93 months for standard-risk (SR) patients (hazard ratio [HR] 1.81; P < 0.001), corresponding to 5-year OS rates of 40% versus 61%. Similarly, median progression-free survival was 21.3 months for HRMM versus 36 months for SR (HR 1.64; P < 0.001). The presence of ≥2 high-risk features identified an ultra-high-risk group (4.4% of patients) with a threefold increased risk of death, compared to SR patients. CGS remained prognostic irrespective of renal dysfunction, stratifying patients with sCr > 1.2 mg/dL (HR 1.71; P < 0.001) and retained prognostic significance across different age groups, transplant eligibility, and treatment eras (pre- and post-2020). The IMS/IMWG CGS effectively stratified patients in a large cohort treated at a tertiary academic center, identifying a substantially high-risk population with poor outcomes despite modern therapies. This validation supports its deployment in clinical practice and research to enhance the precision of risk-adapted management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.